氨甲蝶呤联合R-CHOP化疗方案治疗弥漫大B细胞淋巴瘤患者的效果  

Effects of Methotrexate combined with R-CHOP chemotherapy in treatment of patients with diffuse large B-cell lymphoma

作　　者：李素颜[1] 王利霞[1] 任小晶[1] LI Suyan;WANG Lixia;REN Xiaojing(Department of Hematology and Oncology of Anyang People’s Hospital,Anyang 455000 Henan,China)

机构地区：[1]安阳市人民医院血液肿瘤科,河南安阳455000

出　　处：《中国民康医学》2025年第6期43-46,共4页Medical Journal of Chinese People’s Health

摘　　要：目的:观察氨甲蝶呤联合R-CHOP化疗方案治疗弥漫大B细胞淋巴瘤(DLBCL)患者的效果。方法:回顾性分析2020年2月至2023年5月该院收治的60例DLBCL患者的临床资料,按照治疗方案不同将其分为观察组与对照组各30例。对照组采用R-CHOP化疗方案治疗,观察组在对照组基础上联合氨甲蝶呤治疗。比较两组临床疗效,治疗前后肿瘤标志物[甲胎蛋白(AFP)、癌胚抗原(CEA),糖类抗原125(CA125)、糖类抗原19-9(CA19-9)]、血管内皮生长因子(VEGF)、β2-微球蛋白(β2-MG)、T细胞亚群指标(CD8^(+)、CD4^(+)、CD3^(+)、CD4^(+)/CD8^(+))水平,以及不良反应发生率。结果:两组客观缓解率、疾病控制率比较,差异均无统计学意义(P>0.05);治疗后,两组AFP、CEA、CA125、CA19-9水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);治疗后,两组VEGF、β2-MG水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);治疗后,两组CD4^(+)、CD3^(+)、CD4^(+)/CD8^(+)水平均低于治疗前,但组间比较,差异无统计学意义(P>0.05);两组不良反应发生率比较,差异均无统计学意义(P>0.05)。结论:氨甲蝶呤联合R-CHOP化疗方案治疗DLBCL患者可降低肿瘤标志物、VEGF、β2-MG水平,效果优于单纯R-CHOP化疗方案治疗。Objective:To observe effects of Methotrexate combined with R-CHOP chemotherapy in treatment of patients with diffuse large B-cell lymphoma(DLBCL).Methods:The clinical data of 60 patients with DLBCL admitted to this hospital from February 2020 to May 2023 were retrospectively analyzed.According to different treatment plans,they were divided into observation group and control group,30 cases in each group.The control group was treated with R-CHOP chemotherapy regimen,while the observation group was treated with Methotrexate on the basis of that of the control group.The clinical efficacy,the levels of tumor markers[alpha-fetoprotein(AFP),carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125),carbohydrate antigen 199(CA19-9)],vascular endothelial growth factor(VEGF),β2-microglobulin(β2-MG)and T cell subsets(CD4^(+),CD3^(+),CD4^(+)/CD8^(+))before and after the treatment,and the incidence of adverse reactions were compared between the two groups.Results:There were no significant differences in the objective remission rate and the disease control rate between the two groups(P>0.05).After the treatment,the levels of AFP,CEA,CA125 and CA19-9 in the two groups were lower than those before the treatment,those in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of VEGF andβ2-MG in the two groups were lower than those before the treatment,those in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of CD4^(+),CD3^(+)and CD4^(+)/CD8^(+)in the two groups were lower than those before the treatment,but there were no significant differences between the two groups(P>0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Methotrexate combined with R-CHOP chemotherapy can reduce the levels of tumor markers,VEGF andβ2-MG in the patients with DLBCL.Moreo

关 键 词：氨甲蝶呤 弥漫大B细胞淋巴瘤 肿瘤标志物 T细胞亚群 不良反应 

分 类 号：R733.4[医药卫生—肿瘤]